• Direct Mouse Genotyping Kit Plus Workflow

  2026-08-25

  Shorten mouse genotyping assay timelines by combining direct tissue lysis with high-fidelity PCR in a streamlined workflow. This guide shows how to apply the Direct Mouse Genotyping Kit Plus to colony screening, transgene detection, and gene knockout validation while preserving controls and troubleshooting discipline.

• c-Myc Peptide: Immunoassay Workflow Guide

  2026-08-24

  Use the c-Myc tag peptide as a precise competition control for antibody specificity, epitope accessibility, and tagged-fusion-protein recovery. This practical guide connects that assay function with lessons from IRF3 selective-autophagy research without overstating the peptide as a cell-signaling modulator.

• Polymyxin B Sulfate: Mechanism & Research Use

  2026-08-24

  Polymyxin B sulfate is a cationic polypeptide antibiotic that disrupts Gram-negative bacterial membranes and supports research on multidrug-resistant infections. Its strongest research value is as a membrane-active comparator in Gram-negative bacterial infection research, with separate applications in dendritic cell maturation assay and sepsis and bacteremia models.

• RSL3 Glutathione Peroxidase 4 Inhibitor Workflows

  2026-08-23

  Build reproducible ferroptosis assays with RSL3, a selective GPX4 inhibitor suited to lipid-peroxidation, redox, and RAS-driven cancer studies. This guide connects practical dosing and rescue controls with PERK–SLC7A11 biology for sharper mechanism-of-action conclusions.

• Sunitinib Workflows for RTK and RCC Research

  2026-08-22

  Build reproducible Sunitinib experiments around RTK inhibition, angiogenesis, cell-cycle control, and therapy resistance. This workflow also translates recent TRIB3–SLC7A11/GPX4 findings into practical assays for renal cell carcinoma models.

• Erastin: Reading Ferroptosis Assays by Mechanism

  2026-08-21

  Erastin is a ferroptosis inducer that reveals how cystine deprivation, glutathione loss, iron, and lipid peroxidation converge in vulnerable tumor cells. This guide uses a recent breast cancer study to develop a more rigorous framework for interpreting oxidative cell-death assays.

• Diuron: From Herbicide Mechanism to Renal Risk

  2026-08-20

  Diuron is more than a photosynthesis inhibitor: recent evidence positions it as a useful bridge between plant biology research, environmental toxicology, and mechanistic nephrotoxicity. This article translates JAK2/STAT1 findings into reproducible assay strategy and translational decision-making.

• Anlotinib Hydrochloride in Angiogenesis Assays

  2026-08-20

  Anlotinib hydrochloride enables a practical, multi-pathway strategy for studying VEGFR2, PDGFRβ, and FGFR1-driven angiogenesis. This guide translates published endothelial, aortic-ring, and CAM findings into reproducible assay workflows, controls, and troubleshooting decisions for cancer research.

• SCUBE3 Antibody Targeting: Signaling and Immunity

  2026-08-19

  The reference study identifies secreted SCUBE3 as a multifunctional driver of oncogenic signaling, therapy resistance, and tumor immune suppression. Its neutralizing antibody strategy links extracellular target inhibition with reduced tumor progression and restoration of antitumor immune activity in preclinical models.

• Entecavir and BMS200475 in Chronic Hepatitis B

  2026-08-19

  This reference review positioned Entecavir, also known as BMS200475, as a clinically important advance in chronic hepatitis B by integrating biochemical, cell-based, animal, and trial evidence. Its central implication is that stronger HBV polymerase inhibition can improve viral suppression and liver-related outcomes while delaying resistance, although prolonged therapy remains necessary because intracellular cccDNA persists.

• Live-Dead Cell Staining Kit for TNBC Assays

  2026-08-18

  Use the Live-Dead Cell Staining Kit I to convert treatment-induced changes in mammalian cell survival into a rapid, two-color fluorescence readout. Its Calcein AM/PI workflow is especially useful for screening gramine and separating endpoint viability from mechanistic ferroptosis measurements.

• Tirbanibulin Rewires HPV Signaling in HeLa Cells

  2026-08-18

  A 2024 study in Archives of Dermatological Research shows that tirbanibulin suppresses proliferation of HPV-18-positive HeLa cells while reducing HPV E6/E7 and multiple Src–MEK–ERK pathway proteins. The findings provide a mechanistic framework linking tirbanibulin to altered cell-cycle control, invasion signaling, and apoptosis, while also defining important limits for translation beyond this in vitro model.

• From Modified RNA to Translational Control

  2026-08-17

  A mechanistic and strategic guide to using N1-Methyl-Pseudouridine-5'-Triphosphate in RNA synthesis, translation studies, and emerging RNA-mediated insertion workflows—while keeping translational claims aligned with the evidence.

• HDAC Inhibition Reverses EBV-Driven Plasticity in NPC

  2026-08-17

  The reference study defines a mechanism by which EBV latent membrane protein 1 drives dedifferentiation in nasopharyngeal carcinoma through STAT5A-associated recruitment of HDAC1/2 to the CEBPA locus. Its experiments show that HDAC inhibition can restore CEBPA expression and partially reverse stem-like plasticity, providing a mechanistic basis for differentiation-oriented cancer therapy in solid tumors.

• Grazoprevir Hydrate: From Target to Assay

  2026-08-16

  Grazoprevir hydrate is more than a potent HCV NS3/4A protease inhibitor: it is a useful model for connecting genotype-aware antiviral assays with translational pharmacology. This guide explains how to interpret potency, design controls, and avoid overextending in vitro findings to clinical conclusions.

554 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page